Exploration of the Treatment Trajectory and Drug Resistance Mechanism of Immunotherapy Combined With Chemotherapy in Patients With Advanced Lung Squamous Carcinoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Squamous Cell Lung Cancer
- Sponsor
- Wuhan Union Hospital, China
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- progression-free survival
- Status
- Enrolling By Invitation
- Last Updated
- last year
Overview
Brief Summary
The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.
Detailed Description
The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.
Investigators
Yang Jin
deputy dean
Wuhan Union Hospital, China
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with sq-NSCLC;
- •Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
- •≥ 18 years and ≤ 80 years old;
- •No previous treatment in the lungs or any other organ.
Exclusion Criteria
- •History of cancer treatment;
- •History of other malignant tumors;
- •Irregular treatment or poor compliance;
- •Incomplete clinical information or lost to follow-up.
Outcomes
Primary Outcomes
progression-free survival
Time Frame: A two-year period after starting treatment (Regular follow-up every three months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)
The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Secondary Outcomes
- Overall survival(A three-year period after starting treatment (Regular follow-up every six months after receiving immunotherapy combined with or without chemotherapy as first-line treatment))